A protective chimeric antibody to tick-borne encephalitis virus

Vaccine. 2014 Jun 17;32(29):3589-94. doi: 10.1016/j.vaccine.2014.05.012. Epub 2014 May 14.

Abstract

The efficiency of several mouse monoclonal antibodies (mAbs) specific to the tick-borne encephalitis virus (TBEV) glycoprotein E in post-exposure prophylaxis was assessed, and mAb14D5 was shown to be the most active of all those studied. It was proven that the hybridoma cell line 14D5 produced one immunoglobulin H chain and two L chains. They were used to construct chimeric antibodies ch14D5a and ch14D5b, the affinity constants of which were 2.6 × 10(10)M(-1) and 1.0 × 10(7)M(-1), respectively, according to the SPR-based ProteOn biosensor assay. The neutralization index (IC50) of ch14D5a was 0.04 μg/ml in the focus reduction neutralization test. In in vivo experiments, ch14D5a at a dose of 10 μg/mouse resulted in a 100% survival of the mice infected with 240 LD50 of TBEV. This chimeric antibody is promising for further development of prevention and therapeutic drugs against TBEV.

Keywords: Affinity constant; Chimeric antibody; In vivo protection; Post-exposure prophylaxis; Tick-borne encephalitis virus; Virus neutralization.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antibodies, Monoclonal / immunology
  • Antibodies, Monoclonal, Murine-Derived / immunology*
  • Antibodies, Viral / immunology*
  • Encephalitis Viruses, Tick-Borne / immunology
  • Encephalitis, Tick-Borne / prevention & control*
  • Hybridomas
  • Mice, Inbred BALB C
  • Neutralization Tests
  • Post-Exposure Prophylaxis
  • Viral Envelope Proteins / immunology*

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Murine-Derived
  • Antibodies, Viral
  • Viral Envelope Proteins
  • glycoprotein E, Flavivirus